0001415889-23-014917.txt : 20231108 0001415889-23-014917.hdr.sgml : 20231108 20231108175639 ACCESSION NUMBER: 0001415889-23-014917 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231107 FILED AS OF DATE: 20231108 DATE AS OF CHANGE: 20231108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wingrove Theresa CENTRAL INDEX KEY: 0001510720 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 231389449 MAIL ADDRESS: STREET 1: IMMUNOGEN, INC. STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 4 1 form4-11082023_101132.xml X0508 4 2023-11-07 0000855654 ImmunoGen, Inc. IMGN 0001510720 Wingrove Theresa C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM MA 02451 false true false false SVP OF REGULATORY AFFAIRS 1 Common Stock 2023-11-07 4 M 0 19517 10.65 A 22328 D Common Stock 2023-11-07 4 S 0 19517 16.66 D 2811 D Stock Option (right to buy) 10.65 2023-11-07 4 M 0 19517 0 D 2028-02-15 Common Stock 19517 140483 D Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $16.71, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges. This option was granted on 2/15/2018 and is fully vested as of the transaction date. /s/ Renee Lentini, Attorney-in-Fact 2023-11-08